EGRX - Eagle Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

78.90

-0.44 (-0.55%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	79.34
Open	78.14
Bid	0.00 x 1100
Ask	0.00 x 1000
Day's Range	78.14 - 79.72
52 Week Range	48.84 - 85.66
Volume	141,998
Avg. Volume	248,614

Market Cap	1.188B
Beta	0.78
PE Ratio (TTM)	39.18
EPS (TTM)	2.01
Earnings Date	May 11, 2017 - May 12, 2017
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	78.75

Trade prices are not sourced from all markets

All

News

Press Releases

Markit3 days ago
See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc NASDAQ NMS:EGRX
Zacks7 days ago
Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Top Estimates
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 15.85% and 14.53%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Associated Press7 days ago
Eagle Pharmaceuticals: 2Q Earnings Snapshot
On a per-share basis, the Woodcliff Lake, New Jersey-based company said it had profit of 17 cents. Earnings, adjusted for non-recurring costs and stock option expense, were 95 cents per share. The specialty ...
Business Wire7 days ago
Eagle Pharmaceuticals, Inc. Reports Second Quarter 2018 Results
-- Q2 2018 net income was $0.18 per basic and $0.17 per diluted share and adjusted non-GAAP net income of $0.99 per basic and $0.95 per diluted share --
ACCESSWIRE7 days ago
Eagle Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:30:00 AM Eastern ...
Zacks8 days ago
Emergent (EBS) Q2 Earnings and Revenues Surpass Estimates
Emergent Biosolutions (EBS) rides high on earnings as well as revenue beat in Q2.
Zacks12 days ago
Conatus' (CNAT) Q2 Loss Narrows, Revenues Lag Marginally
Conatus (CNAT) incurs narrower-than-expected loss in Q2. Sales miss estimates.
Zacks14 days ago
NuVasive (NUVA) in Focus: Stock Moves 6.02% Higher
NuVasive (NUVA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Zacks15 days ago
Is Eagle Pharmaceuticals (EGRX) Stock Outpacing Its Medical Peers This Year?
Is (EGRX) Outperforming Other Medical Stocks This Year?
Business Wire20 days ago
Eagle Pharmaceuticals, Inc. to Discuss Second Quarter 2018 Financial Results on August 7, 2018
Eagle Pharmaceuticals, Inc. today announced that the Company will release its 2018 second quarter financial results on Tuesday, August 7, 2018, before the market opens.
Markit28 days ago
See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc NASDAQ NMS:EGRX
Business Wirelast month
FDA Grants Eagle Seven Year Orphan Drug Exclusivity for BENDEKA (bendamustine hydrochloride injection)
Eagle Pharmaceuticals, Inc. (EGRX) (“Eagle” or the “Company”) announced today that the U.S. Food and Drug Administration (FDA) has granted seven years of orphan drug exclusivity (ODE) in the U.S., for BENDEKA™ (bendamustine hydrochloride injection, or bendamustine HCI), a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine hydrochloride. As a result, and consistent with the order issued by the U.S. District Court for the District of Columbia (the Court) on June 8, 2018, the FDA will not approve any drug applications referencing BENDEKA until the ODE expires in December 2022.
Business Wirelast month
Eagle Pharmaceuticals Announces New Patent Issued for BENDEKA
-- BENDEKA protected by 15 patents running from 2026 through 2033 –
GlobeNewswire2 months ago
Investor Expectations to Drive Momentum within Education Realty Trust, Eagle Pharmaceuticals, Boingo Wireless, United Parcel Service, Marathon Petroleum, and Coherent — Discovering Underlying Factors of Influence
NEW YORK, June 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Education ...
Market Realist2 months ago
Teva’s Key Drugs in Its Specialty Products Pipeline
Teva Pharmaceutical’s (TEVA) fremanezumab is a key product awaiting FDA approval. The drug is also under Phase 2 trials for the treatment of post-traumatic headache and a Phase 3 trial for the treatment of cluster headache. The drug is expected to generate significant sales for the company in the years ahead. Teva’s specialty products pipeline is shown in the chart below.
Benzinga2 months ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! NANO DIMENSION/S ADR (NASDAQ: NNDM ) stock was trading ...
Market Realist2 months ago
Teva Stock Could Jump after Good News from Partner Manufacturers
Eagle Pharmaceuticals (EGRX), a US-based drug maker and a partner of Teva Pharmaceutical that specializes in the development of critical care drugs, won a lawsuit against the US FDA. The FDA had refused to grant orphan drug status to Teva Pharmaceutical and Eagle Pharmaceuticals’ Bendeka (bendamustine hydrochloride) for the treatment of individuals with chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. The orphan drug status will grant Teva Pharmaceutical an extra seven years of patent protection and market exclusivity.
Business Wire2 months ago
Court Issues Decision in Favor of Eagle Pharmaceuticals Granting Seven Year Orphan Drug Exclusivity for BENDEKA (bendamustine hydrochloride injection)
Eagle Pharmaceuticals, Inc. (EGRX) (“Eagle” or the “Company”) announced today that the U.S. District Court for the District of Columbia (the Court) has issued a decision requiring the FDA to grant seven years of orphan drug exclusivity (ODE) in the U.S., for BENDEKA™ (bendamustine hydrochloride injection, or bendamustine HCI), a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine hydrochloride. As a result of the Court’s decision, the FDA will not be able to approve any drug applications referencing BENDEKA until the ODE expires in December 2022.
Business Wire2 months ago
Eagle Pharmaceuticals, Inc. to Present at Investor Conferences in June
Eagle Pharmaceuticals, Inc. announced today that management will present at two investor conferences in June as follows:
ACCESSWIRE3 months ago
Wired News – FDA Granted Approval to Eagle Pharma’s Bendamustine Hydrochloride RTD Solution in a 500ml Admixture
LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want access to our free research report on Eagle Pharma, Inc. (NASDAQ: EGRX) ("Eagle"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EGRX as the Company's latest news hit the wire. On May 16, 2018, the Company announced that the US Food and Drug Administration (FDA) has granted final approval to the Company's ready-to-dilute (RTD) bendamustine hydrochloride (HCl) solution in a 500ml admixture for the treatment of patients with chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Active-Investors.com is currently working on the research report for Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), which also belongs to the Healthcare sector as the Company Eagle Pharma.
GlobeNewswire3 months ago
Market Trends Toward New Normal in Agios Pharmaceuticals, Corcept Therapeutics, Prestige Brand, Virtu Financial, Eagle Pharmaceuticals, and Century Aluminum — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, May 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Agios ...
Business Wire3 months ago
Eagle Pharmaceuticals, Inc. Granted Final FDA Approval for Bendamustine Hydrochloride Ready-to-Dilute Solution in a 500ml Admixture
Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (EGRX) today announced that the U.S. Food and Drug Administration (FDA) has granted final approval for Eagle’s ready-to-dilute (RTD) bendamustine hydrochloride (HCl) solution in a 500ml admixture for the treatment of patients with chronic lymphocytic leukemia (CLL) and patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Eagle’s bendamustine HCl injection does not require reconstitution and is administered as a 500ml admixture over 30 or 60 minutes. Based upon our view of the market, we anticipate over time achieving up to a 12% market share, increasing our overall profitability,” stated Scott Tarriff, Chief Executive Officer of Eagle Pharmaceuticals.
Thomson Reuters StreetEvents3 months ago
Edited Transcript of EGRX earnings conference call or presentation 10-May-18 12:30pm GMT
Q1 2018 Eagle Pharmaceuticals Inc Earnings Call
Associated Press3 months ago
Eagle Pharmaceuticals: 1Q Earnings Snapshot
On a per-share basis, the Woodcliff Lake, New Jersey-based company said it had profit of 17 cents. Earnings, adjusted for stock option expense and non-recurring costs, came to 53 cents per share. The specialty ...
Business Wire3 months ago
Eagle Pharmaceuticals, Inc. Reports First Quarter 2018 Results
Eagle Pharmaceuticals, Inc. today announced its financial results for the three months ended March 31, 2018. Highlights of and subsequent